After Eli Lilly announced it received a Complete Response Letter, or CRL, from the FDA for its biologic license application for Mirikizumab, or miri, for ulcerative colitis, or UC, BofA analyst Geoff Meacham says the firm looks for "modest pressure on shares" due to the news. However, the "implications are modest," says the firm, which notes that according to Lilly the FDA cited only manufacturing issues. The issue was identified at one of Lilly’s internal Indianapolis sites, rather than a third party CMO, but the team stressed there was unlikely to be any impact on other products, added BofA, which has a Buy rating on Lilly with a $390 price target and says the growth thesis remains "intact."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Eli Lilly CRL ‘disappointing,’ but impact ‘likely limited,’ says Morgan Stanley
- Eli Lilly receives complete response letter from FDA for mirikizumab
- Eli Lilly price target lowered to $392 from $395 at Guggenheim
- Eli Lilly price target raised to $448 from $444 at Morgan Stanley
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports